NCT07033689 2026-04-03
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
SONIRE Therapeutics Inc.
Phase EARLY_PHASE1 Recruiting
SONIRE Therapeutics Inc.
OHSU Knight Cancer Institute
CHU de Quebec-Universite Laval
Northwell Health
University of California, Davis
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
First Affiliated Hospital of Wenzhou Medical University
Poitiers University Hospital